Gel4Med
Gel4Med is a commercial-stage company pioneering the use of smart, bioinspired materials to address major challenges in medicine. Founded out of Harvard Innovation Labs, Gel4Med leverages its proprietary Smart Materials Platform™ (SMP™) to develop advanced therapeutics and devices, with a mission to enhance health outcomes and access for all patients. The company is committed to creating novel biomaterials that improve regenerative medicine and surgical solutions, and has achieved significant milestones including FDA clearance for its lead wound care product, G4Derm™ Plus.
Industries
Nr. of Employees
small (1-50)
Gel4Med
1660 Soldiers Field Road, STE 7, #1063, Brighton MA 02135
Products
Flowable biomimetic matrix wound-care system (prefilled sterile syringe)
A synthetic, peptide-based flowable matrix supplied in a prefilled sterile syringe with a flexible applicator tip; designed to form a 3D scaffold that mimics extracellular matrix to support tissue regrowth and provide an antibacterial barrier in wound beds.
Flowable biomimetic matrix wound-care system (prefilled sterile syringe)
A synthetic, peptide-based flowable matrix supplied in a prefilled sterile syringe with a flexible applicator tip; designed to form a 3D scaffold that mimics extracellular matrix to support tissue regrowth and provide an antibacterial barrier in wound beds.
Expertise Areas
- Peptide-based biomaterials engineering
- Regenerative medicine and tissue engineering
- Advanced wound care product development
- Preclinical and translational research
Key Technologies
- Self-assembling peptide materials
- Molecular sequence-driven material design
- Stimuli-responsive biomaterials
- Flowable shear-thinning hydrogel formulations
Key People
Co-Founder & CEO
Associate Director- Product Development
Scientist- Biomaterials
Scientist- Cell & Tissue Biology
Clinical Operations Manager
Senior Product Manager
Co-Founder & CEO
Associate Director- Product Development
Scientist- Biomaterials
Scientist- Cell & Tissue Biology
Clinical Operations Manager
Senior Product Manager
News & Updates
Gel4Med received its first FDA 510(k) market clearance for G4Derm™/G4Derm™ Plus, marking a significant milestone for its lead wound care asset.
Gel4Med was awarded highly competitive funding from the NIH SBIR program to advance its wound care and surgical reconstruction portfolio.
Gel4Med received significant funding from the NIH CRP program for the commercial launch of its lead asset.
Gel4Med and the University of Miami were awarded significant funding from the CDMRP/DoD for collaborative research on novel spinal cord injury treatments.
G4Derm™ Plus Biomimetic Matrix was featured in the August 2025 issue of Podiatry Management Magazine, highlighting its wound healing capabilities.
A case series published by Massachusetts General Hospital / Harvard Medical School highlighted rapid healing of diabetic foot ulcers using G4Derm™ Plus.
Gel4Med received its first FDA 510(k) market clearance for G4Derm™/G4Derm™ Plus, marking a significant milestone for its lead wound care asset.
Gel4Med was awarded highly competitive funding from the NIH SBIR program to advance its wound care and surgical reconstruction portfolio.
Gel4Med received significant funding from the NIH CRP program for the commercial launch of its lead asset.
Gel4Med and the University of Miami were awarded significant funding from the CDMRP/DoD for collaborative research on novel spinal cord injury treatments.
G4Derm™ Plus Biomimetic Matrix was featured in the August 2025 issue of Podiatry Management Magazine, highlighting its wound healing capabilities.
A case series published by Massachusetts General Hospital / Harvard Medical School highlighted rapid healing of diabetic foot ulcers using G4Derm™ Plus.